Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. Academic Article uri icon

Overview

abstract

  • The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma.

publication date

  • December 1, 2020

Research

keywords

  • Guidelines as Topic
  • Immunotherapy
  • Lymphoma

Identity

PubMed Central ID

  • PMC7768967

Scopus Document Identifier

  • 85098334003

Digital Object Identifier (DOI)

  • 10.1136/jitc-2020-001235

PubMed ID

  • 33361336

Additional Document Info

volume

  • 8

issue

  • 2